Multiple myeloma is a cancer of plasma cells, the immune cells in the bone marrow that normally produce antibodies. In myeloma, a single abnormal plasma-cell population multiplies and produces an abnormal antibody, antibody fragment or, less commonly, no measurable protein.
The abnormal plasma cells can crowd out healthy blood-forming cells, weaken bones, increase calcium levels, impair kidney function and reduce normal antibody production. Myeloma may affect several areas of bone marrow and bone simultaneously rather than forming one localised tumour.
Multiple myeloma may be preceded by monoclonal gammopathy of undetermined significance or smouldering multiple myeloma. These precursor conditions do not automatically require treatment. Active myeloma is diagnosed when clonal plasma cells or a biopsy-proven plasmacytoma occur with myeloma-related organ damage or another accepted myeloma-defining event.
Related plasma-cell disorders include solitary plasmacytoma, light-chain myeloma, non-secretory myeloma, plasma-cell leukaemia and amyloidosis. Accurate classification is essential because monitoring and treatment differ between these conditions.
At Apollo Cancer Centres, multiple myeloma care is planned by a multidisciplinary team that may include haemato-oncologists, transplant and cellular-therapy specialists, pathologists, molecular-diagnostics specialists, nephrologists, radiation oncologists, orthopaedic or spine surgeons and supportive-care professionals.
Risk Factors for Multiple Myeloma
Multiple Myeloma Signs and Symptoms
How Multiple Myeloma is Diagnosed
Multiple myeloma is diagnosed by combining blood and urine tests, bone-marrow assessment and imaging. A monoclonal protein alone does not establish active myeloma because it can also occur in MGUS, smouldering myeloma and other plasma-cell or lymphoid disorders.
The diagnosis generally requires at least 10% clonal plasma cells in the bone marrow or a biopsy-proven plasmacytoma, together with a myeloma-defining event. These events include myeloma-related organ damage or biomarkers associated with a very high risk of near-term progression.
Organ damage is commonly summarised as CRAB: raised calcium, renal impairment, anaemia and bone lesions. Additional myeloma-defining biomarkers include a very high clonal marrow plasma-cell percentage, a markedly abnormal involved-to-uninvolved serum free light-chain ratio and more than one focal lesion on MRI, when accepted thresholds are met.
Whole-Body Low-Dose CT
Whole-body low-dose CT is commonly used to detect bone destruction caused by myeloma. It is more sensitive than a traditional skeletal survey for identifying small lytic lesions. The scan examines the skull, spine, ribs, pelvis and long bones. It can identify fractures, vertebral collapse and areas at risk of breaking. It does not reliably show early marrow-only disease before bone destruction develops. CT findings contribute directly to the diagnosis of active myeloma when one or more qualifying lytic lesions are identified. Urgent MRI may still be required when spinal-cord compression is suspected.
PET-CT Scan
FDG PET-CT detects metabolically active myeloma in the bone marrow, bones and tissues outside the bone marrow. It can assess the extent of disease, identify a suitable biopsy site and provide a baseline for response assessment. PET-CT may be particularly useful for extramedullary disease and evaluating whether previously active lesions remain metabolically active after treatment. A lytic lesion seen on the CT component can satisfy bone-disease criteria even when tracer uptake is limited. Inflammation, infection and healing fractures may also show increased uptake. Results must therefore be interpreted with the clinical findings, laboratory results and other imaging.
MRI
MRI is highly sensitive for detecting abnormal bone-marrow involvement before bone destruction becomes visible on CT. Whole-body or spine and pelvic MRI may be used when initial imaging is negative or smouldering myeloma is being evaluated. More than one qualifying focal MRI lesion can constitute a myeloma-defining biomarker. MRI also shows vertebral fractures, nerve compression and soft-tissue extension. Urgent MRI is required when spinal-cord or cauda equina compression is suspected. The scan helps determine whether corticosteroids, radiation or surgery is required. MRI findings alone cannot determine the plasma-cell subtype and must be correlated with bone-marrow and protein studies.
X-ray Skeletal Survey
A skeletal survey uses a series of X-rays to look for lytic lesions and fractures. It was historically a standard part of myeloma assessment but is less sensitive than whole-body low-dose CT, PET-CT or MRI. X-rays may still be used when advanced whole-body imaging is unavailable or to assess a specific painful area. A normal skeletal survey does not exclude myeloma bone disease. Degenerative changes and osteoporosis must be distinguished from myeloma-related lesions.
Echocardiogram
An echocardiogram may be performed when the patient has cardiac symptoms, known heart disease or suspected amyloidosis. It may also provide a baseline before selected treatments. An electrocardiogram and cardiac biomarkers may be added according to symptoms and the planned regimen. Heart findings can influence fluid management, medicine choice and transplant eligibility. Cardiac assessment is not required in the same form for every patient.
Bone-Marrow Aspiration
Bone-marrow aspiration removes liquid marrow, usually from the back of the hip bone. The sample is examined to determine the proportion and appearance of plasma cells. It also provides cells for flow cytometry, chromosome analysis and molecular testing. Flow cytometry confirms that the plasma cells are clonal and identifies their immunophenotype. The aspirate may underestimate disease when plasma cells are distributed unevenly. Bone-marrow aspiration may be repeated to assess response or measurable residual disease. Temporary soreness or bruising can occur at the sampling site.
Bone-Marrow Biopsy
Bone-marrow biopsy removes a small core of bone and marrow, often during the same procedure as aspiration. It shows the pattern and extent of plasma-cell infiltration more clearly. Immunohistochemistry identifies plasma-cell markers and demonstrates light-chain restriction. The biopsy may reveal fibrosis, amyloid or another marrow disorder. Aspiration and biopsy findings are interpreted together because myeloma involvement can be patchy.
Biopsy of a Bone or Soft-Tissue Lesion
A biopsy may be required when imaging identifies a solitary bone lesion or soft-tissue mass and the diagnosis is uncertain. The tissue is examined for clonal plasma cells and amyloid when relevant. Biopsy helps distinguish plasmacytoma from metastatic cancer, lymphoma or another bone tumour. Blood, urine, bone-marrow and whole-body imaging are still necessary because an apparently solitary lesion may be part of systemic myeloma.
Kidney Biopsy
Kidney biopsy is not routinely required when the pattern of myeloma-related kidney injury is clear. It may be considered when the cause of renal dysfunction is uncertain or when another kidney disease could change treatment. The procedure examines kidney tissue for light-chain cast nephropathy, amyloidosis, light-chain deposition disease or an unrelated disorder. Bleeding risk, platelet count and kidney size are assessed beforehand. The decision is made jointly by the haemato-oncology and nephrology teams.
Laboratory
Blood, urine and bone-marrow samples undergo biochemical, immunological, pathological, cytogenetic and molecular assessment. Testing may include:
Complete blood count: Measures haemoglobin, white blood cells and platelets and may show anaemia or other cytopenias.
Peripheral blood smear: Examines blood-cell appearance and may show rouleaux formation or, rarely, circulating plasma cells.
Calcium: Detects hypercalcaemia caused by increased bone breakdown.
Creatinine and estimated glomerular filtration rate: Assess kidney function and guide medicine dosing.
Liver function tests: Assess organ health and treatment suitability.
Albumin: Contributes to staging and provides information about inflammation and nutrition.
Beta-2 microglobulin: Reflects disease burden and kidney function and contributes to staging.
LDH: Provides prognostic information and may indicate biologically aggressive disease.
Serum protein electrophoresis: Detects and measures a monoclonal protein in the blood.
Serum immunofixation: Identifies the type of heavy and light chain produced by the abnormal plasma cells.
Quantitative immunoglobulins: Measure normal and abnormal antibody levels.
Serum free light-chain assay: Measures kappa and lambda light chains and calculates the involved-to-uninvolved ratio.
Urine protein electrophoresis: Detects monoclonal light chains and measures urinary protein.
Urine immunofixation: Identifies the type of monoclonal protein present in urine.
Twenty-four-hour urine protein assessment: May quantify monoclonal protein and total protein loss in selected patients.
Bone-marrow morphology: Determines the proportion and appearance of plasma cells.
Flow cytometry: Confirms a clonal plasma-cell population and may be used for response assessment.
FISH testing: Identifies abnormalities such as deletion 17p, gain or amplification of 1q and selected immunoglobulin heavy-chain translocations.
Chromosome analysis: Detects broader chromosome changes, although plasma cells may divide slowly in laboratory culture.
Measurable residual disease testing: Highly sensitive flow cytometry or sequencing can detect small numbers of myeloma cells after treatment.
Infection screening: May include hepatitis B, hepatitis C, HIV and other infections before immunosuppressive treatment.
HLA typing: May be considered if an allogeneic transplant is being evaluated, although this is uncommon in myeloma.
Changes in the monoclonal protein and serum free light chains help assess treatment response. Results must be interpreted according to the type of myeloma because some patients produce little or no measurable protein.
Multiple myeloma is not staged using the conventional solid-tumour TNM system. The Revised International Staging System combines beta-2 microglobulin, albumin, LDH and selected high-risk chromosome abnormalities.
Stage I: Stage I disease has a beta-2 microglobulin level below the defined threshold, an albumin level at or above the required level, normal LDH and no recognised high-risk chromosome abnormality.
Stage II: Stage II includes disease that does not meet the criteria for stage I or stage III.
Stage III: Stage III disease has a high beta-2 microglobulin level together with either an elevated LDH or a recognised high-risk chromosome abnormality.
How Multiple Myeloma is Treated
Initial Treatment for Transplant-Eligible Patients
Transplant-eligible patients generally receive several cycles of induction treatment to reduce the plasma-cell burden before stem-cell collection. Induction commonly combines a proteasome inhibitor, an immunomodulatory medicine and a corticosteroid. Bortezomib, lenalidomide and dexamethasone form a frequently used three-drug regimen. An anti-CD38 antibody such as daratumumab may be added for eligible patients. Other combinations may be selected according to kidney function, cytogenetic risk, neuropathy and medicine availability. Stem cells are collected after an adequate response and before prolonged exposure to medicines that may reduce collection yield. Autologous transplantation is then performed immediately or, in selected circumstances, reserved for first relapse. Treatment decisions consider disease risk, depth of response and patient preference.
Initial Treatment for Transplant-Ineligible Patients
Patients who are not candidates for immediate transplantation receive a regimen adapted to fitness rather than chronological age alone. Options may include daratumumab with lenalidomide and dexamethasone or a modified proteasome inhibitor-based combination. Fit older adults may tolerate a three- or four-drug regimen, while frail patients may require fewer medicines or lower doses. Frailty assessment considers mobility, other illnesses, cognition and ability to manage daily activities. Dose adjustment is important because infection, low blood counts, neuropathy, fatigue and falls can interfere with treatment. The aim is sustained disease control while preserving function and quality of life.
Proteasome Inhibitors
Proteasome inhibitors interfere with the mechanisms myeloma cells use to break down unwanted proteins. Bortezomib, carfilzomib and ixazomib are used in different frontline, maintenance or relapse settings. Bortezomib is particularly useful when kidney function is impaired and can be administered beneath the skin. Peripheral neuropathy can occur, although subcutaneous and less frequent dosing reduce risk. Carfilzomib may be effective in selected relapsed or high-risk disease but requires assessment of heart function, blood pressure and fluid balance. Ixazomib is an oral medicine used in selected combinations. Antiviral prophylaxis is generally required because proteasome inhibitors increase the risk of shingles.
Immunomodulatory Medicines
Lenalidomide, pomalidomide and thalidomide affect myeloma cells and modify immune responses. They are combined with corticosteroids and other medicines rather than ordinarily used alone. These medicines can cause low blood counts, infection and blood clots. Aspirin or anticoagulation may be required according to the patient's clotting risk and treatment combination. Lenalidomide dosing must be adjusted for kidney function. Thalidomide can cause significant neuropathy and constipation. Strict pregnancy-prevention measures are required because these medicines can cause severe fetal harm.
Anti-CD38 Antibodies
Daratumumab and isatuximab target CD38 on plasma cells. They may be incorporated into frontline or relapsed-disease combinations. Infusion- or injection-related reactions are most common during initial doses. Antiviral prophylaxis and infection monitoring are required. Treatment can interfere with blood-bank compatibility testing, so the transfusion service should receive a baseline sample before therapy begins. Anti-CD38 therapy can also interfere with some response tests by appearing as a small monoclonal protein. Specialist laboratory methods may be needed to distinguish the medicine from residual disease.
Corticosteroids
Dexamethasone and prednisolone can directly suppress plasma cells and strengthen the effect of other myeloma medicines. They are included in many combination regimens. Potential effects include high blood sugar, infection, insomnia, mood changes, muscle weakness, indigestion and bone loss. Dose reduction is often appropriate for older or frail patients. Patients should not stop prolonged corticosteroid treatment abruptly without medical guidance. Diabetes medicines and infection-prevention strategies may require adjustment during therapy.
Maintenance Therapy
Maintenance treatment aims to prolong remission after induction and, when performed, autologous transplantation. Lenalidomide is commonly used for standard-risk disease. A proteasome inhibitor or combination maintenance may be considered for selected high-risk disease. Anti-CD38-containing maintenance strategies may also be used according to the preceding regimen, response and treatment protocol. Maintenance is generally continued while it remains beneficial and tolerable. Blood counts, kidney function, infection risk and disease markers are monitored. The benefits are balanced against fatigue, cytopenias, second-cancer risk and quality of life.
Treatment of Bone Disease
Bisphosphonates such as zoledronic acid or pamidronate reduce skeletal complications. Denosumab may be considered, particularly when kidney function limits bisphosphonate use. Calcium, vitamin D, kidney function and dental health are assessed before and during treatment. Osteonecrosis of the jaw is uncommon but important. A dental evaluation and completion of necessary invasive dental work are recommended before long-term bone-modifying therapy when possible. Pain management, physiotherapy, fall prevention and appropriate physical activity help preserve mobility. Weight-bearing exercise must be adapted to fracture risk and spinal stability.
Management of Kidney Impairment
Myeloma-related kidney impairment requires rapid assessment and treatment. Effective anti-myeloma therapy, often including bortezomib and corticosteroids, should begin promptly when light-chain injury is suspected. Hydration is managed carefully according to heart and kidney function. High calcium, infection and dehydration are corrected. Medicines that can worsen kidney function, including non-steroidal anti-inflammatory drugs, are generally avoided. Dialysis may be required for severe kidney failure. Mechanical removal of free light chains has not replaced effective systemic treatment and is considered only in selected circumstances. Nephrology and haemato-oncology teams coordinate care.
Treatment of Hypercalcaemia
Hypercalcaemia is treated with hydration, rapid myeloma control and a bone-modifying medicine when appropriate. Calcitonin may be used temporarily when calcium is severely elevated and rapid reduction is required. Kidney and heart function influence the amount and rate of intravenous fluid. Calcium levels, electrolytes and urine output are monitored. Confusion, severe weakness, dehydration or heart-rhythm changes require urgent treatment.
Treatment of Relapsed or Refractory Myeloma
Relapsed myeloma returns after a response, while refractory disease progresses during treatment or shortly afterwards. Therapy is selected according to medicines previously received, resistance, duration of response, cytogenetic risk, symptoms and patient fitness. Options may include proteasome inhibitors, immunomodulatory medicines, anti-CD38 antibodies, targeted combinations, antibody–drug conjugates where available, bispecific antibodies, CAR T-cell therapy or another autologous transplant. A medicine from a previously effective class may sometimes be reused after a sufficiently long response. Repeat bone-marrow and molecular assessment may be performed when disease behaviour changes. Clinical trials are particularly important for disease resistant to several major treatment classes.
Autologous Stem-Cell Transplantation
Autologous stem-cell transplantation is an established treatment for eligible patients with newly diagnosed multiple myeloma. The patient's own stem cells are collected after induction therapy. High-dose melphalan is then administered to reduce residual myeloma, after which the stored stem cells are returned to restore blood-cell production. Transplantation deepens response and prolongs disease control but is not generally considered curative. Potential complications include infection, bleeding, mouth soreness, diarrhoea, infertility and temporary severe bone-marrow suppression. Eligibility depends on fitness, organ function and patient preference rather than a strict age threshold alone. A second autologous transplant may be considered for selected patients who had a durable response to the first. Tandem transplantation may be considered in particular high-risk situations, depending on the treatment strategy.
Allogeneic Stem-Cell Transplantation
Allogeneic transplantation uses stem cells from a compatible donor and can produce a graft-versus-myeloma effect. Its role is limited because treatment-related complications are substantially greater than with autologous transplantation. It may be considered for a small group of younger, fit patients with very high-risk or repeatedly relapsed disease, preferably within a clinical trial. Reduced-intensity conditioning may be used to lower immediate toxicity. Risks include severe infection, organ toxicity, graft failure, infertility, graft-versus-host disease and treatment-related mortality. The decision requires careful comparison with CAR T-cell therapy, bispecific antibodies and other available treatments.
CAR T-Cell Therapy
CAR T-cell therapy modifies the patient's own T cells to recognise a target on myeloma cells. Current myeloma CAR T-cell treatments generally target B-cell maturation antigen, or BCMA. The patient's T cells are collected and genetically modified before being returned through an intravenous infusion. Lymphodepleting chemotherapy is administered shortly before the infusion. Manufacturing takes time, so bridging treatment may be required to control the disease. Potential complications include cytokine-release syndrome, neurological effects, infection, prolonged low blood counts and reduced normal antibody levels. Treatment is delivered at a specialised cellular-therapy centre with close monitoring.
CAR T-cell therapy may be considered for eligible patients with relapsed or refractory myeloma according to previous therapy, regulatory approval and availability. It is not required for most newly diagnosed patients.
Bispecific Antibody Therapy
Bispecific antibodies connect myeloma cells with the patient's T cells. Available treatments may target BCMA or other plasma-cell proteins such as GPRC5D. These medicines may be considered for selected patients with myeloma that has progressed after several previous treatment classes. Unlike CAR T-cell therapy, they are manufactured in advance and do not require individual cell collection. Potential complications include cytokine-release syndrome, infection, low blood counts, reduced antibody levels and target-specific effects. Step-up dosing and close monitoring are used during initial treatment. Infection prevention and immunoglobulin support may be required.
Radiation for Bone Pain
Radiation may relieve pain from a localised bone lesion that remains symptomatic despite systemic treatment and pain medicines. Myeloma cells are generally sensitive to radiation. The treatment area and schedule depend on the site, fracture risk, previous radiation and general health. Pain relief may begin during treatment or over the following weeks. Radiation does not strengthen an unstable bone immediately. Orthopaedic assessment may be required when a weight-bearing bone is at risk of fracture.
Radiation for Spinal-Cord Compression
Spinal-cord compression is an emergency. Corticosteroids and urgent MRI are generally required, followed by radiation, surgery or both according to spinal stability and neurological findings. Radiation can reduce the plasma-cell mass pressing on the spinal cord. Treatment should begin promptly when surgery is not required or is unsuitable. Neurological recovery depends partly on how quickly compression is treated. New limb weakness, numbness or bladder or bowel dysfunction requires emergency assessment.
Radiation for Solitary Plasmacytoma
A solitary plasmacytoma is a localised collection of clonal plasma cells without systemic myeloma-defining features. Definitive radiation is the standard treatment for most solitary bone and extramedullary plasmacytomas. The treatment area includes the visible lesion with an appropriate margin. Surgery may be required for structural stabilisation, neurological compression or diagnostic uncertainty. Long-term follow-up is essential because some patients later develop multiple myeloma. Monitoring includes blood and urine protein studies, free light chains and imaging when indicated.
Radiation for Extramedullary Disease
Radiation may treat a soft-tissue plasma-cell mass causing pain, bleeding or organ compression. It may also be used when an isolated site does not respond adequately to systemic treatment. Because extramedullary disease may occur with active myeloma elsewhere, systemic therapy usually remains necessary. Radiation planning protects nearby organs and considers previous treatment.
Palliative Radiation Therapy
Short-course radiation may relieve pain or pressure from one or more symptomatic lesions. The schedule is designed to limit treatment burden while providing local control. Pain medicines, bone-modifying treatment and systemic therapy continue as appropriate. Palliative radiation treats the selected area but does not control myeloma throughout the body.
Multiple myeloma is generally considered treatable but not routinely curable. Modern combinations, transplantation, maintenance treatment and immune-based therapies can produce deep and prolonged remissions.
The disease course varies considerably. Some patients respond for many years, while high-risk or treatment-resistant myeloma may return more quickly.
Follow-up includes clinical assessment, blood counts, kidney function, calcium, monoclonal-protein testing and serum free light chains. Imaging and bone-marrow examination are performed when clinically indicated.
Long-term care addresses infection risk, bone health, kidney function, neuropathy, blood clots, fertility, emotional well-being and treatment-related effects.
Why Choose ACC for Multiple Myeloma Treatment